Stephen M. Stahl, MD, PhD, DSc (Hon.)
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA
Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK
Editor-in-Chief, CNS Spectrums
Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA
Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the Honors Program in Medical Education, and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.
Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as professor at the University of California at San Diego (UCSD) and as an Honorary Visiting Senior Fellow in the Department of Psychiatry at the University of Cambridge in the UK. He also directs psychopharmacology services and academic programs for the eight-facility, 6500 patient California Department of State Hospital System, where he also heads their assessment and treatment efforts to reduce violence. Dr. Stahl was formerly Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.
Dr. Stahl currently serves as editor-in-chief of CNS Spectrums. He is also past associate editor of Acta Psychiatrica Scandinavica, former clinical field editor for the International Journal of Neuropsychopharmacology and is currently on numerous editorial boards of other leading journals including the ACNP’s journal Neuropsychopharmacology. He has conducted numerous research projects during his career awarded by the National Institute of Mental Health (NIMH), by the Department of Veteran Affairs (VA) and by the pharmaceutical industry. Author of over 500 articles and chapters, and more than 1600 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 35 books and edited 12 others, including the best-selling and award-winning textbook, Stahl’s Essential Psychopharmacology, now in its fourth edition, the best-selling and award winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its sixth edition.
Lectures, courses and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels. His lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages. His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world.
Dr. Stahl serves as a fellow of the ACNP (American College of Neuro-psychopharmacology), of the British Association of Psychopharmacology (BAP) and of the CINP, where he was formerly vice president and is a Distinguished Life Fellow of the American Psychiatric Association (APA). He also has served on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California and past Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).
His educational research programs are monitoring changes in diagnosing and prescribing behaviors as outcomes from various educational interventions for programs organized by the Neuroscience Education Institute, which he chairs. He also has an active clinical practice specializing in psychopharmacologic treatment of resistant cases.
He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology. His books have won the British Medical Association’s Book of the Year Award and Arbor Scientia has been awarded the business of the year award from the local chamber of commerce. Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD department of psychiatry residency teaching award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecture for 2013. Recently, his alma mater Northwestern University honored him by naming their annual award for the best medical student going into psychiatry the Stephen Stahl award. Dr. Stahl was named the 2016 David A Mrazek Memorial Award Winner by the American Psychiatric Association and delivered the Mrazek Lecture at the annual meeting of the APA.
Roger S. McIntyre, MD, FRCPC
Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada
Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.
Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.
Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
|| Laxman B. Bahroo, DO
Associate Professor, Department of Neurology, MedStar Georgetown University Medical Center, Washington, DC
Director, Residency Program, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC
Dr. Laxman B. Bahroo is an assistant and co-director of the Neurology Residency Program at MedStar Georgetown University Hospital. He attended medical school in New Jersey, and he completed an internship at Saint Luke's Hospital in Bethlehem, Pa. Dr. Bahroo completed his neurology residency as served as the Academic Chief Resident in his final year at MedStar Georgetown University Hospital. He also completed a two-year fellowship in movement disorders at MedStar Georgetown University Hospital. As a board-certified neurologist and member of the Movement Disorders program, his primary areas of focus in movement disorders include the medical and surgical management of Parkinson's disease and essential tremor. He also specializes in therapeutic botulinum toxin injections for dystonia spasticity and excessive drooling.
|| Leslie Citrome, MD, MPH
Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY
Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation.
Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.
Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.
|| Andrew J. Cutler, MD
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Dr. Andrew J. Cutler attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology. He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his Medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD. Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He has been Board Certified in both Internal Medicine and Psychiatry.
Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.
Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.
Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.
|| Kari L. Franson, PharmD, PhD, BCPP
Associate Dean, Academic and Student Affairs; Professor, Department of Clinical Pharmacy, University of Southern California, Los Angeles, CA
Dr. Kari L. Franson joined the University of Southern California in 2020 as the Associate Dean for Academic and Student Affairs and Professor of Clinical Pharmacy. Dr. Franson received her Doctor of Pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in Medical Education from Leiden University, the Netherlands.
Dr. Franson is an educator with more than 25 years of experience. Throughout her career, she has focused on two areas: health professions education and psychopharmacology.
She is an international leader in interprofessional practice, education and advocacy and workforce development to address health disparities in both the US and abroad. Dr. Franson has experience in campus and distance-based curriculum development and assessment, technology-enhanced assessment/learning, experiential education, and continuing professional education and development.
Dr. Franson is a U.S. Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects and cannabis user safety. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.
|| David W. Goodman, MD, FAPA
Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD
Director and Founder, Adult Attention Deficit Disorder Center of Maryland, Baltimore, MD
Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.
|| Rona J. Hu, MD
Clinical Professor, Department of Psychiatry and Behavioral Sciences; Medical Director, Acute Psychiatric Inpatient Unit, Stanford University School of Medicine, Stanford, CA
Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.
Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998.
Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.
|| Rajnish Mago, MD
Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Dr. Rajnish Mago is the founder and editor-in-chief of simpleandpractical.com, a website which provides clinical summaries and advanced tips to help mental health clinicians become expert psychopharmacologists. He is a clinical professor of psychiatry at SUNY Upstate Medical University in Syracuse, NY and a clinical assistant professor of psychiatry at the University of Pennsylvania in Philadelphia, PA, where he is the director of the psychopharmacology curriculum. Dr. Mago was previously a professor of psychiatry and director of the mood disorders program at Thomas Jefferson University in Philadelphia, PA.
Dr. Mago is equally a clinician, researcher, and educator, with each of these areas informing the others.
As a clinician, he provides specialized consultation as well as ongoing care to patients with mood disorders, anxiety disorders, and ADHD.
As a researcher and academic, he has done studies on tools for identifying and assessing symptoms that may be adverse effects, on the treatment of side effects like antidepressant-induced excessive sweating, and on the use of genetic testing to predict who may be more likely to have adverse effects.
As an educator, his practical guides in psychopharmacology are helping thousands of mental health clinicians in over 70 countries. At the University of Pennsylvania in Philadelphia, PA, where he is a clinical assistant professor, he has designed a four-year psychopharmacology curriculum and also personally teaches psychopharmacology to psychiatry residents. He is also actively involved in continuing medical education in his capacity as chair of the education committees for both the Pennsylvania Psychiatric Society and the Philadelphia Psychiatric Society. Dr. Mago is also an associate editor of the periodical Current Psychiatry.
Dr. Mago has been widely recognized for being an exceptional teacher and has received many awards for his teaching. These include the APA’s Nancy C.A. Roeske MD Certificate of Recognition for Excellence in Medical Student Education (2010) and the Irma Bland Award for Excellence in Teaching Residents (2011); the Philadelphia Psychiatric Society’s Daniel Blain Award (2011), the Robert Waelder Award for teaching from the graduating residents (Class of 2012) at Thomas Jefferson University; the Dean’s Award for Excellence in Education at Jefferson Medical College (2013); and the Philadelphia Psychiatric Society’s award for being the Psychiatric Educator of the Year (2014).
|| Jonathan M. Meyer, MD
Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA
Dr. Jonathan M. Meyer is a graduate of Stanford University and Harvard Medical School and finished his adult psychiatry residency at Los Angeles County-USC Medical Center. At LA County-USC he subsequently completed fellowships in Consultation/Liaison Psychiatry and Psychopharmacology Research.
In addition to teaching duties at UC San Diego, Dr. Meyer has performed extensive research on the metabolic effects of antipsychotics, and the impact of antipsychotic medications on glucose-insulin homeostasis. Dr. Meyer has published numerous articles and book chapters on various aspects of antipsychotic psychopharmacology including the pharmacokinetics of oral and depot antipsychotics, metabolic effects of atypical antipsychotics, as well as on the health care outcomes in patients with severe mental illness. Dr. Meyer is a national speaker on the subject of side effects and metabolic issues surrounding antipsychotic therapy, is chief editor of Medical Illness and Schizophrenia, now in its 2nd edition, and is the sole author of the chapter on the “Pharmacotherapy of Psychosis and Mania” in the last two editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics.
|| Adelaide S. Robb, MD
Distinguished Endowed Professor and Chair, Division of Psychiatry and Behavioral Sciences, Center for Neuroscience and Behavioral Medicine, Children’s National Health System, George Washington University School of Medicine & Health Sciences, Washington, DC
Dr. Adelaide S. Robb is a psychopharmacologist with ongoing research studies in depression and mood disorders, anxiety and attention deficit disorder. She is Chief of the Division of Psychiatry and Behavioral Sciences.
Dr. Robb, who trained at Johns Hopkins University and the National Institutes of Health, has been on the medical staff in the Division of Psychiatry and Behavioral Medicine since 1996, rising to the rank of Professor (with tenure). She is an internationally known clinical researcher and has participated in and led multiple therapeutic trials for children with a variety of behavioral and psychiatric conditions.
Dr. Robb is currently a tenured Professor of Psychiatry and of Pediatrics at George Washington University School of Medicine and Health Sciences and Director of Psychiatry Research at the Center for Translation Science within Children’s National. Dr. Robb’s research focus is in psychopharmacology.
|| William M. Sauvé, MD
Regional Medical Director, Virginia; Greenbrook TMS NeuroHealth Centers
Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines.
After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well.
He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.
|| Thomas L. Schwartz, MD
Professor and Interim Chair, Department of Psychiatry and Behavioral Sciences; Senior Associate Dean for Education; SUNY Upstate Medical University, Syracuse, NY
Dr. Thomas L. Schwartz is active on many teaching, administrative and curriculum committees at SUNY, he also provides direct resident supervision, lectures in several courses, and directs and organizes continuing medical education events for the psychiatry department.
Dr. Schwartz received his medical degree from and completed his residency in adult psychiatry at the State University of New York (SUNY) Upstate Medical University in Syracuse, New York.
Dr. Schwartz’s abilities as a medical educator have been recognized with the Marc H. Hollander, MD, Psychiatry Award, Teacher of the Year, and Mentor of the Year awards from SUNY Upstate Medical University; Nancy Roeske, MD, Irma Bland, Certificates of Recognition for Excellence in Medical Student and Resident Education from the American Psychiatric Association, the SUNY Upstate President’s and the SUNY Chancellor’s Award for Teaching.
Dr. Schwartz is the author of Practical Psychopharmacology: Basic to Advanced Principles, "Stahl’s Essential Psychopharmacology” Case Studies Volume 2, Integrating Psychotherapy and Pharmacotherapy, Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, Second and Third Generation Antipsychotics. He is the editor of Depression: Treatment Strategies and Management, 1st and 2nd Eds. and is the Deputy Editor for the journal CNS Spectrums.
|| Manpreet K. Singh, MD, MS
Associate Professor, Division of Child and Adolescent Psychiatry; Director, Pediatric Mood Disorders Program; Director, Pediatric Emotion and Resilience Lab; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.
Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.
Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.
In her spare time, Dr. Singh enjoys traveling and hiking with her husband and three children, and avidly teaches Indian classical music.
|| Jeffrey R. Strawn, MD
Associate Professor, Departments of Pediatrics and of Psychiatry and Behavioral Neuroscience, University of Cincinnati, College of Medicine, Cincinnati, OH
Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents. His examination of cortical thickness in adolescents with anxiety, revealed abnormalities in cortical thickness in an ensemble of regions responsible for fear learning, fear extinction, reflective functioning (e.g., mentalization), and regulation of the amygdala. Additionally, gray matter volumes in youth with anxiety disorders are greater in the dorsal anterior cingulate and decreased in the ventrolateral prefrontal cortex), cuneus/precuneus, as well as decreased amygdala gray matter volumes in the amygdala which is consistent with his functional MRI data suggesting increased activation in youth with anxiety disorders, relative to healthy comparison subjects, during a continuous processing task with emotional and neutral distractors. Additionally, from a neurochemistry standpoint, he has demonstrated that glutamatergic tone in the anterior cingulate cortex is directly linked with anxiety symptom severity in youth with anxiety. These studies suggest that anxiety disorders are associated with structural, functional and neurochemical abnormalities with prefrontal-amygdala circuitry. By providing evidence of these structural, functional and neurochemical abnormalities, this body of work has propelled additional studies of these structures in youth who are at risk for developing anxiety disorders and in studies which have allowed the integration of psychopharmacologic treatment studies with neuroimaging evaluations of anxious youth.
In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. As an example, with his collaborators, they demonstrated the efficacy of duloxetine in a double-blind placebo controlled trial of duloxetine which culminated in a FDA indication for duloxetine in children and adolescents with GAD (age 7-17).
|| Katherine Warburton, DO
Medical Director and Deputy Director of Clinical Operations, California Department of State Hospitals, Sacramento, CA
Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law.
|| Timothy E. Wilens, MD
Chief, Division of Child and Adolescent Psychiatry; Director, Substance Abuse Services in Pediatric Psychopharmacology; Co-Director, Center for Addiction Medicine; Massachusetts General Hospital for Children, Boston, MA
Professor, Department of Psychiatry, Harvard Medical School, Boston, MA
Dr. Timothy E. Wilens is chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital (MGH), (co) director of the Center for Addiction Medicine at MGH, and the MGH Trustees Chair in Addiction Medicine. He is a professor of Psychiatry at Harvard Medical School.
Dr. Wilens earned his BS in literature, science, and arts at the University of Michigan Honors College and his MD at the University of Michigan Medical School in Ann Arbor. His residency in child, adolescent and adult psychiatry was completed at Massachusetts General Hospital under the auspices of Harvard Medical School. He is triple board certified in child/adolescent, adult, and addiction psychiatry.
Dr. Wilens’ research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models, and the pharmacotherapy of ADHD across the lifespan. He has published more than 300 peer-reviewed articles, concerning these and related topics, in prestigious journals such as JAMA, American Journal of Psychiatry, Archives of General Psychiatry, and Pediatrics. Dr. Wilens has also coedited/published more than 80 book chapters, 4 books, and 300 abstracts and presentations for national and international scientific meetings.
Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry (AACAP), serves as the chair of new research and psychopharmacology committees for AACAP, is on the editorial boards or is a scientific reviewer for more than 35 journals, and is active in a number of other local and national professional societies.
Dr. Wilens is named consistently among “The Best of Boston” in Child/Adult Psychiatry and “The Best Doctors in America.”
|| Deborah A. York, MSN, PMHNP-BC, APRN, CCRA
Adjunct Professor, University of Cincinnati College of Nursing, Cincinnati, OH
Private Practice, Salida and Pueblo, CO
Founder, Mountain Mind, LLC, Colorado Springs and Pueblo, CO
Ms Deborah A. York is currently a board certified Psychiatric-Mental Health Nurse Practitioner in private practice in Colorado Springs, CO. She is Adjunct Professor at the College of Nursing at the University of Cincinnati and Director of Clinical Research at Mountain Mind. She completed her Bachelor of Science in Nursing at the University of Missouri-St. Louis at Barnes College of Nursing, Washington University, and her research certification as a Certified Clinical Research Associate at the Association of Clinical Research Professionals.
Ms York then completed her Master’s Degree at the University of Cincinnati in Nurse Midwifery and later her Post-Master’s Certificate at the University of Cincinnati in Psychiatry-Mental Health. Additionally, she is certified through the Academy for Preventive and Innovative Medicine by WorldLink Medical in Bioidentical Hormone Replacement Therapy. She has spent over 25 years in the clinical trials industry conducting clinical research on novel pharmacological interventions specializing in biologics, Women’s Health, CNS and Psychiatry clinical trials.
Ms York has a clinical focus in endocrine psychiatry for the treatment of a variety of psychiatric illnesses with specialized expertise in pharmacological treatments of mood disorders involving menopause, andropause, PMS, PMDD and post-partum depression. Her research focus is conducting clinical trials to identify and evaluate novel psychopharmacological and neuroradiological interventions for traumatic brain injury, mood disorders, and pediatric psychiatric illnesses that may substantially improve patient outcomes.
Ms York is also actively involved in teaching nursing students in the Psychiatric-Mental Health Post-Master’s Certificate program at the University of Cincinnati with a central focus on implementation of evidence-based practices in specialized mental health care settings.